- Home
- MNMD vs ODV Comparison
MNMD vs ODV Comparison
Compare MNMD & ODV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNMD
- ODV
- Stock Information
- Founded
- MNMD 2019
- ODV 2005
- Country
- MNMD United States
- ODV Canada
- Employees
- MNMD N/A
- ODV N/A
- Industry
- MNMD Pharmaceuticals and Biotechnology
- ODV Precious Metals
- Sector
- MNMD Health Care
- ODV Basic Materials
- Exchange
- MNMD Nasdaq
- ODV Nasdaq
- Market Cap
- MNMD 960.2M
- ODV 866.1M
- IPO Year
- MNMD N/A
- ODV N/A
- Fundamental
- Price
- MNMD $13.39
- ODV $3.07
- Analyst Decision
- MNMD Strong Buy
- ODV
- Analyst Count
- MNMD 7
- ODV 0
- Target Price
- MNMD $26.71
- ODV N/A
- AVG Volume (30 Days)
- MNMD 1.8M
- ODV 2.2M
- Earning Date
- MNMD 10-31-2025
- ODV 11-07-2025
- Dividend Yield
- MNMD N/A
- ODV N/A
- EPS Growth
- MNMD N/A
- ODV N/A
- EPS
- MNMD N/A
- ODV N/A
- Revenue
- MNMD N/A
- ODV $5,147,156.00
- Revenue This Year
- MNMD N/A
- ODV $317.30
- Revenue Next Year
- MNMD N/A
- ODV $40.73
- P/E Ratio
- MNMD N/A
- ODV N/A
- Revenue Growth
- MNMD N/A
- ODV N/A
- 52 Week Low
- MNMD $4.70
- ODV $1.16
- 52 Week High
- MNMD $14.30
- ODV $3.89
- Technical
- Relative Strength Index (RSI)
- MNMD 60.21
- ODV 43.03
- Support Level
- MNMD $12.41
- ODV $2.93
- Resistance Level
- MNMD $13.74
- ODV $3.14
- Average True Range (ATR)
- MNMD 0.84
- ODV 0.21
- MACD
- MNMD -0.06
- ODV -0.08
- Stochastic Oscillator
- MNMD 52.55
- ODV 13.44
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).
About ODV Osisko Development Corp.
Osisko Development Corp is a mineral exploration and development company engaged in the acquisition, exploration, and development of precious metals resource properties in North America. The company is focused on exploring and developing its mining assets, including the Cariboo Gold Project in British Columbia, the San Antonio gold project in Mexico, and the Trixie test mine in the USA. The Company manages its business through the exploration, evaluation, and development activities of its projects.